Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

A key weight-loss drug goes off-patent next year. A US study estimates its production cost to be less than 2% of its selling ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

A WOMAN has shared the brutally honest truth about what happened when she was forced to ”go cold turkey” from Mounjaro.

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

It turns out that obesity may be much more complicated than we thought, with the condition potentially existing in up to 11 ...